Forte Biosciences, Inc. - Common Stock (FBRX)
CUSIP: 34962G208
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 12,506,886
- Total 13F shares
- 4,275,821
- Share change
- +3,539,179
- Total reported value
- $97,104,372
- Price per share
- $22.71
- Number of holders
- 26
- Value change
- +$81,936,549
- Number of buys
- 14
- Number of sells
- 10
Quarterly Holders Quick Answers
What is CUSIP 34962G208?
CUSIP 34962G208 identifies FBRX - Forte Biosciences, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 34962G208:
Top shareholders of FBRX - Forte Biosciences, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13D/G
|
— |
8%
|
510,000
|
$3,763,800 | $0 | 31 Dec 2024 | |
| PERCEPTIVE ADVISORS LLC |
13D/G
13F
|
Company |
2.5%
|
163,935
|
$1,209,840 | $0 | 31 Dec 2024 | |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD |
13F
|
Company |
1.2%
|
144,981
|
$810,444 | — | 30 Sep 2024 | |
| BVF INC/IL |
13F
|
Company |
0.95%
|
119,282
|
$667,979 | — | 30 Sep 2024 | |
| FRED ALGER MANAGEMENT, LLC |
13F
|
Company |
0.66%
|
82,698
|
$462,282 | — | 30 Sep 2024 | |
| Cable Car Capital, LP |
13F
|
Company |
0.65%
|
81,279
|
$454,350 | — | 30 Sep 2024 | |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.58%
|
72,413
|
$405,513 | — | 30 Sep 2024 | |
| BML Capital Management, LLC |
13F
|
Company |
0.56%
|
70,468
|
$393,916 | — | 30 Sep 2024 | |
| Hubert C. Chen |
3/4/5
|
President and Chief Scientific Officer |
—
mixed-class rows
|
183,405
mixed-class rows
|
$150,704 | — | 01 Jan 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.21%
|
26,394
|
$147,807 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.11%
|
14,270
|
$79,930 | — | 30 Sep 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.1%
|
13,096
|
$73,338 | — | 30 Sep 2024 | |
| BlackRock, Inc. |
13F
|
Company |
0.05%
|
6,803
|
$38,029 | — | 30 Sep 2024 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.05%
|
6,000
|
$33,540 | — | 30 Sep 2024 | |
| Farallon Capital Partners, L.P. |
13D/G
|
Dapice Joshua J. |
3.4%
|
221,027
|
$12,130 | $0 | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
0.01%
|
1,606
|
$8,978 | — | 30 Sep 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
806
|
$4,506 | — | 30 Sep 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
559
|
$3,130 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
151
|
$844 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
23
|
$129 | — | 30 Sep 2024 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
20
|
$112 | — | 30 Sep 2024 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0%
|
18
|
$100 | — | 30 Sep 2024 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
8
|
$45 | — | 30 Sep 2024 | |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA |
13F
|
Company |
0%
|
7
|
$32 | — | 30 Sep 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
3
|
$17 | — | 30 Sep 2024 | |
| REAP Financial Group, LLC |
13F
|
Company |
0%
|
3
|
$17 | — | 30 Sep 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0%
|
1
|
$6 | — | 30 Sep 2024 | |
| Donald Allen Williams |
3/4/5
|
Director |
—
class O/S missing
|
50,000
|
— | — | 20 Aug 2024 | |
| Lawrence Eichenfield |
3/4/5
|
Director |
—
class O/S missing
|
50,000
|
— | — | 20 Aug 2024 | |
| Patricia S. Walker |
3/4/5
|
Director |
—
class O/S missing
|
25,000
|
— | — | 01 Jun 2022 |
Institutional Holders of Forte Biosciences, Inc. - Common Stock (FBRX) as of Q4 2024
As of 31 Dec 2024,
Forte Biosciences, Inc. - Common Stock (FBRX) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,275,821 shares.
The largest 10 holders included
FRED ALGER MANAGEMENT, LLC, TYBOURNE CAPITAL MANAGEMENT (HK) LTD, Ikarian Capital, LLC, ORBIMED ADVISORS LLC, BVF INC/IL, Cable Car Capital, LP, Woodline Partners LP, PERCEPTIVE ADVISORS LLC, BOOTHBAY FUND MANAGEMENT, LLC, and FARALLON CAPITAL MANAGEMENT LLC.
This page lists
26
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
23
Q4 2024 holders
26
Holder diff
3
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.